Bibliographic Details
| Title: |
Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe |
| Authors: |
Enver Aydilek, Gerald Wulf, Friedrich Schwarz, Ulrike Bacher, Mathias Rummel, Olga Stiefel, Andrea Kerkhoff, Markus Maulhardt, Thomas Melchardt, Thomas Pabst, Georg Lenz, Evgenii Shumilov |
| Source: |
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024) |
| Publisher Information: |
Wiley, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
compassionate use program, mantle cell lymphoma, outcomes, pirtobrutinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Abstract Background Mantle cell lymphoma (MCL) is a type of B‐cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real‐world data are scarce. Methods In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP). Results On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow‐up of 8.6 months, the mean duration of response (DOR), progression‐free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented. Conclusions In summary, pirtobrutinib represented a safe and effective treatment option in a small real‐world population. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2045-7634 |
| Relation: |
https://doaj.org/toc/2045-7634 |
| DOI: |
10.1002/cam4.7289 |
| Access URL: |
https://doaj.org/article/82ba4619d0c3405eb19265e1022f290e |
| Accession Number: |
edsdoj.82ba4619d0c3405eb19265e1022f290e |
| Database: |
Directory of Open Access Journals |
